An interventional study of Cold atmospheric plasma (CAP) and Sham Procedure in Diabetic Foot Ulcers (DFU) and Lower Extremity Arterial Occlusion, sponsored by Shenyang Medical College. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Shenyang Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Diabetic Foot with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Diabetic Foot · China.
Among the 52 studies in Diabetic Foot with a site in China, this one is the 17th largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, reaches primary completion later than 10 of the 23 other live ones, and was the 44th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →21 of the 52 studies in Diabetic Foot with a site in China are open now. Recruiting first, the newest first:
Nanchong Central Hospital · Sites in China
Ages 18+
Shenyang Medical College · Sites in China
Ages 18–80
Zhongda Hospital · Sites in China
Ages 18–75
The First Hospital of Jilin University · Sites in China
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 5 · Phase 4 6
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 70 across the 41 interventional studies, 200 across the 11 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 52 have an industry lead sponsor. The 10 most frequent:
Shenyang Medical College is the lead sponsor of 12 studies on the registry; 10 are open to participants now.
Shenyang Medical College has 2 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetic Foot with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT07740707Nanchong Central HospitalShort-term SCS for Refractory Diabetic Foot Neuropathic Pain | 2027-03-01 |
| NCT07482137Zhongda HospitalTherapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Diabetic Foot with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Critical limb ischemia is the end-stage manifestation of peripheral arterial disease (PAD), frequently presenting as ischemic rest pain, ulceration, or gangrene. Diabetes mellitus is a major risk factor for lower extremity arterial occlusion, with infrapopliteal arteries most commonly affected. Patients with diabetic foot ulcers (DFUs) have a high prevalence of neurovascular complications, poor healing, and elevated amputation and mortality rates. Large-scale cohort studies indicate that five-year survival after amputation in this population is only about 50%, underscoring the need for more effective therapies.
Endovascular revascularization has become the first-line treatment for diabetic lower limb ischemia. However, despite successful revascularization, persistent microvascular dysfunction and difficult-to-heal ulcers remain common due to chronic inflammation, impaired angiogenesis, and tissue repair deficits. Current advanced wound dressings provide limited benefit and are often costly.
Cold atmospheric plasma (CAP) has emerged as a promising adjunctive therapy, with demonstrated antimicrobial activity-including efficacy against multidrug-resistant organisms-and the ability to promote microcirculation and wound healing. CAP generates reactive oxygen and nitrogen species that disrupt bacterial membranes and may also stimulate tissue regeneration. Preclinical and clinical studies suggest that CAP can accelerate healing in chronic wounds and is well tolerated by patients.
Given these advantages, the present study aims to assess the efficacy and safety of CAP combined with endovascular intervention in patients with diabetic foot ulcers and lower extremity arterial occlusion, to inform future clinical application of this novel technology.
End-stage peripheral arterial disease (PAD) is characterized by critical limb ischemia, which manifests clinically as insufficient arterial perfusion leading to ischemic rest pain, ulceration, and gangrene. A substantial proportion of these cases occur in patients with diabetes complicated by lower extremity arterial occlusion. Ischemia in diabetic patients predominantly affects infrapopliteal arteries, often presenting bilaterally and symmetrically, with diffuse lesions that commonly involve the entire vessel wall. These patients are more prone to both intimal atherosclerosis and medial arterial calcification.
A large multicenter cohort study in China that enrolled 669 patients with diabetic foot ulcers from 15 tertiary hospitals reported that more than 98% had underlying neurovascular pathology. The overall amputation rate was 19.03%, with major and minor amputation rates of 2.14% and 16.88%, respectively. Notably, the five-year survival rate after amputation was approximately 50%, which is lower than that observed for many malignancies. According to a large European cohort study, about half of diabetic foot ulcers are attributable to neuropathic or ischemic etiologies. Both macrovascular and microvascular dysfunctions jointly impair tissue perfusion and exacerbate diabetic foot pathology. From a clinical perspective, successful arterial revascularization alone is not sufficient; maintenance and optimization of distal microcirculatory perfusion following revascularization are also essential for effective ulcer healing.
With advances in endovascular techniques, infrapopliteal angioplasty has become the first-line treatment for diabetic lower limb ischemia, with proven efficacy. However, even after successful revascularization, some patients continue to suffer from inadequate distal perfusion due to microembolization or from persistent, hard-to-heal ulcers driven by the underlying pathophysiology of diabetic wounds. Several studies have demonstrated that diabetic patients experience metabolic dysregulation, local wound hyperglycemia, and accumulation of advanced glycation end-products (AGEs); combined with immune dysfunction and chronic inflammation, these factors maintain wounds in a persistent inflammatory state. Chronic inflammation suppresses vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG-1) expression, impairs endothelial cell function, and leads to angiogenesis disorders and delayed tissue repair. Reduced VEGF and ANG-1 expression has been confirmed in skin specimens from diabetic patients. In addition, peripheral neuropathy further inhibits neovascularization.
Despite widespread clinical use of advanced wound dressings-such as hydrogels, natural or synthetic polymer-based products, and other dressings designed specifically for diabetic ulcers-treatment efficacy remains limited, and costs can be substantial. For patients with diabetic foot ulcers complicated by large-vessel occlusion, ongoing assessment and support of distal microvascular perfusion remain a major unmet clinical need, even after successful revascularization.
Cold atmospheric plasma (CAP) has been widely adopted in medical applications and has demonstrated robust antimicrobial activity as well as the capacity to enhance tissue microcirculation and promote wound healing, with excellent patient tolerance. Multiple preclinical and clinical studies have confirmed the bactericidal efficacy of CAP, including activity against multidrug-resistant organisms. For example, Brun et al. reported that CAP effectively eradicates Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) in vitro, achieving results comparable to antibiotics but with higher efficiency. Lis et al. found that CAP could also inactivate MRSA, Klebsiella pneumoniae, and Acinetobacter baumannii. Korean researchers Kim et al. demonstrated that CAP effectively disrupts biofilms formed by P. aeruginosa and other pathogens in canine skin and ear infections. In a prospective clinical study, Stratmann et al. showed that CAP treatment accelerates wound healing in diabetic foot ulcers. Boekema et al. [6] reported a significant reduction in bacterial load and no serious adverse events in patients with P. aeruginosa infections treated with CAP, confirming its safety profile.
The antimicrobial mechanism of CAP is primarily attributed to the generation of reactive oxygen and nitrogen species (RONS), which induce local free radical formation and disrupt microbial membranes, leading to apoptosis without fostering antimicrobial resistance. This highlights CAP as a valuable adjunct to conventional antibiotic therapy, especially for wounds infected with multidrug-resistant bacteria.
Importantly, CAP's benefits extend beyond antimicrobial effects. Numerous studies indicate that CAP promotes wound healing not only by eliminating pathogens but also by directly activating tissue regeneration. At the cellular level, CAP has been shown to modulate fibroblasts, vascular endothelial cells, and keratinocytes. Stratmann et al. observed that CAP enhanced tissue regeneration in diabetic foot ulcers without a corresponding decrease in colony-forming units, suggesting a regeneration mechanism independent of bactericidal action. In the study by Brehmer et al., CAP (PlasmaDerm device) significantly improved healing rates in lower extremity venous ulcers compared with standard care. These findings imply that CAP can accelerate tissue regeneration and shorten healing time, regardless of its antimicrobial effects.
Delayed wound healing is often accompanied by local microcirculatory disorders, resulting in decreased collagen production and impaired proliferation and migration of keratinocytes and fibroblasts. Several clinical trials have demonstrated that CAP exposure at therapeutic doses increases local skin blood flow and tissue oxygen saturation without raising skin temperature. The underlying mechanism may involve nitric oxide (NO) permeation, modulation of cysteine disulfide bonds and acidic lipid groups, reduced local pH, and improved microcirculation. In animal and cellular experiments, Arndt et al. demonstrated that CAP induces oxidative stress pathways in a paracrine and autocrine manner, stimulating keratinocytes, fibroblasts, and endothelial cells to produce vascular growth factors (EGF, FGF-2, IL-8, uPA, angiopoietin, VEGF), thereby promoting angiogenesis.
Based on these findings, this study aims to evaluate the efficacy and safety of CAP combined with endovascular intervention in patients with diabetic foot ulcers complicated by lower extremity arterial occlusion, providing essential evidence to support future large-scale clinical application of CAP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Cold atmospheric plasma (CAP) · Other: Successful infrapopliteal angioplasty
Device: Sham Procedure · Other: Successful infrapopliteal angioplasty
CAP therapy will be administered once daily for the first five days and then every other day thereafter, for a total of 13 sessions. Each session will last approximately 25 minutes, as recommended by the manufacturer. During treatment, the affected limb will be enclosed in a sterile treatment bag, sealed with medical adhesive tape. The CAP device will operate in two sequential modes: a "disinfection mode" delivering ozone-rich (O₃) plasma-activated gas for 20 minutes, followed by a "healing mode" delivering nitric oxide (NO)-rich plasma-activated gas for 5 minutes. All procedures will be performed in accordance with the manufacturer's instructions and the device's standard operating protocol.
Participants in the placebo group will undergo a sham procedure, in which the electric field required for plasma generation will be disabled, so that no plasma will be produced. Only the operating sounds of the device will be simulated, ensuring blinding for both participants and clinical staff.
All patients will undergo successful infrapopliteal angioplasty, with less than 30% residual stenosis confirmed by digital subtraction angiography.
Change in ulcer area between groups
The ulcer area (cm²) will be measured daily during the first five days, and every other day for the subsequent eight visits (13 follow-up assessments in total)
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Time to 10% reduction in ulcer area
The time from randomization to the first occurrence of a 10% reduction in ulcer area
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Time to 20% reduction in ulcer area
The time from randomization to the first occurrence of a 20% reduction in ulcer area.
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Time to onset of clinical signs of infection
The time from randomization to the first documented clinical sign of wound infection.
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Change in pain score
Change in pain score, assessed by the Visual Analogue Scale (VAS; 0 = no pain, 10 = worst imaginable pain; higher scores indicate greater pain severity)
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Change in quality of life (EQ-5D questionnaire)
Time frame: Baseline (Day 0) and Day 21 post-randomization
Change in quality of life (SF-12 questionnaire)
Time frame: Baseline (Day 0) and Day 21 post-randomization
Incidence of local skin irritation
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Incidence of local bleeding
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Incidence of local burning sensation
Time frame: From Baseline (Day 0) to Day 21 post-randomization
Change in pain score
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
Change in quality of life (EQ-5D questionnaire)
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
Change in quality of life (SF-12 questionnaire)
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
Incidence of keloid formation
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
Incidence of amputation
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
All-cause mortality
Time frame: Baseline (Day 0), Day 180 ± 15, and Day 360 ± 20 post-randomization
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2026, 8 months after the start.
Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 8 months is below that.
Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenyang Medical College